Statements (27)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
gptkbp:administeredBy |
subcutaneous injection
|
gptkbp:approvalYear |
2017
|
gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
gptkbp:ATCCode |
gptkb:R03DX10
|
gptkbp:brand |
gptkb:Fasenra
|
gptkbp:CASNumber |
gptkb:1044511-01-3
|
gptkbp:developedBy |
gptkb:AstraZeneca
|
gptkbp:drugClass |
gptkb:anti-interleukin-5_receptor_monoclonal_antibody
|
gptkbp:eliminationHalfLife |
15-20 days
|
gptkbp:hasMolecularFormula |
C6508H10004N1732O2032S46
|
https://www.w3.org/2000/01/rdf-schema#label |
benralizumab
|
gptkbp:legalStatus |
prescription only
|
gptkbp:mechanismOfAction |
induces apoptosis of eosinophils
|
gptkbp:pregnancyCategory |
not assigned (consult physician)
|
gptkbp:routeOfAdministration |
subcutaneous
|
gptkbp:sideEffect |
headache
injection site reaction pharyngitis |
gptkbp:target |
gptkb:interleukin-5_receptor_alpha_(IL-5Rα)
|
gptkbp:UNII |
3ZJ8Q3183V
|
gptkbp:usedFor |
severe eosinophilic asthma
|
gptkbp:bfsParent |
gptkb:IL5
gptkb:Fasenra |
gptkbp:bfsLayer |
6
|